Episode
Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro
- Podcast
- Hims House
- Published
- Aug 26, 2026
- Duration seconds
- 3629
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/bijan-salehizadeh-eli-lilly-s-war-on-compounded-glp-1s-peptides-retatrutide-and-hims-vs-ro/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/bijan-salehizadeh-eli-lilly-s-war-on-compounded-glp-1s-peptides-retatrutide-and-hims-vs-ro.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, founding investor in Auris Health. Bijan holds no position in HIMS. The conversation opens on the FDA: why Heidi Overton is "moldable clay," her 30-40% confirmation odds, and why pharma prefers interim commissioner Kyle Diamantis. They then move to Eli Lilly's multi-front war on compounded GLP-1s, the ReviveRx suit, the effort to pull semaglutide and tirzepatide off the 503B bulks list, and Bijan's theory of a "grand bargain" trading compounding restrictions for Medicare pricing cooperation. He walks through the retatrutide biologic fight ahead of the September 24th appellate argument in Chicago, and why Hims' 76% gross margins are gone for good as branded dispensing grows. They close on peptides: Bijan has heard Category 1 rulemaking *could* come as soon as November, and he thinks the market could be 10x bigger than current estimates. 00:00 - Sponsor: Superpower 01:16 - No one knows anything about Heidi Overton (FDA nominee) 06:29 - Eli Lilly's war on 503A pharmacies 08:47 - The Lilly "grand bargain" 13:49 - When compounding becomes a "new drug" 17:34 - Branded drugs crush margins 21:51 - Hims management scorecard 26:29 - Retatrutide reclassification fight 35:10 - Suing the reta gray market vendors 37:06 - Why the Wegovy pill is beating Foundayo 40:56 - Europe is a second-tier market 42:15 - Can LillyDirect beat telehealth? 46:14 - Peptides Wild West 50:51 - Category 1 by November? 52:40 - Peptides market 10x bigger than estimates 55:56 - Will Ro go public? 58:34 - Bullish $HIMS long term Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discuss…